{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"Hodgkin lymphoma unsuitable for ABVD","name":"PLIMATH","nct_id":"NCT03331731","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=plimath-nct03331731. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PLIMATH","arms":[{"description":"Single Arm","label":"Single arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-08-31","type":"ACTUAL"},"conditions":["Hodgkin Lymphoma"],"enrollment":{"count":27,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-11-02","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"A Multi-centre Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma Considered Unsuitable for ABVD","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Response using Lugano Criteria","timeFrame":"At each treatment cycle 1 to 35 (each cycle is 3 weeks)"}],"references":[],"start_date":{"date":"2018-11-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT03331731"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/plimath-nct03331731"}